Precision recruitment for high-risk participants in a COVID-19 cohort study.

CDC, Centers for Disease Control and Prevention COVID-19 Clinical trials GAMs, generalized additive models Risk modeling

Journal

Contemporary clinical trials communications
ISSN: 2451-8654
Titre abrégé: Contemp Clin Trials Commun
Pays: Netherlands
ID NLM: 101671157

Informations de publication

Date de publication:
Jun 2023
Historique:
received: 28 11 2022
revised: 07 03 2023
accepted: 10 03 2023
entrez: 20 3 2023
pubmed: 21 3 2023
medline: 21 3 2023
Statut: ppublish

Résumé

Studies for developing diagnostics and treatments for infectious diseases usually require observing the onset of infection during the study period. However, when the infection base rate incidence is low, the cohort size required to measure an effect becomes large, and recruitment becomes costly and prolonged. We developed a model for reducing recruiting time and resources in a COVID-19 detection study by targeting recruitment to high-risk individuals. We conducted an observational longitudinal cohort study at individual sites throughout the U.S., enrolling adults who were members of an online health and research platform. Through direct and longitudinal connection with research participants, we applied machine learning techniques to compute individual risk scores from individually permissioned data about socioeconomic and behavioral data, in combination with predicted local prevalence data. The modeled risk scores were then used to target candidates for enrollment in a hypothetical COVID-19 detection study. The main outcome measure was the incidence rate of COVID-19 according to the risk model compared with incidence rates in actual vaccine trials. When we used risk scores from 66,040 participants to recruit a balanced cohort of participants for a COVID-19 detection study, we obtained a 4- to 7-fold greater COVID-19 infection incidence rate compared with similar real-world study cohorts. This risk model offers the possibility of reducing costs, increasing the power of analyses, and shortening study periods by targeting for recruitment participants at higher risk.

Sections du résumé

Background UNASSIGNED
Studies for developing diagnostics and treatments for infectious diseases usually require observing the onset of infection during the study period. However, when the infection base rate incidence is low, the cohort size required to measure an effect becomes large, and recruitment becomes costly and prolonged. We developed a model for reducing recruiting time and resources in a COVID-19 detection study by targeting recruitment to high-risk individuals.
Methods UNASSIGNED
We conducted an observational longitudinal cohort study at individual sites throughout the U.S., enrolling adults who were members of an online health and research platform. Through direct and longitudinal connection with research participants, we applied machine learning techniques to compute individual risk scores from individually permissioned data about socioeconomic and behavioral data, in combination with predicted local prevalence data. The modeled risk scores were then used to target candidates for enrollment in a hypothetical COVID-19 detection study. The main outcome measure was the incidence rate of COVID-19 according to the risk model compared with incidence rates in actual vaccine trials.
Results UNASSIGNED
When we used risk scores from 66,040 participants to recruit a balanced cohort of participants for a COVID-19 detection study, we obtained a 4- to 7-fold greater COVID-19 infection incidence rate compared with similar real-world study cohorts.
Conclusion UNASSIGNED
This risk model offers the possibility of reducing costs, increasing the power of analyses, and shortening study periods by targeting for recruitment participants at higher risk.

Identifiants

pubmed: 36938318
doi: 10.1016/j.conctc.2023.101113
pii: S2451-8654(23)00059-5
pmc: PMC10008035
doi:

Types de publication

Journal Article

Langues

eng

Pagination

101113

Informations de copyright

© 2023 Published by Elsevier Inc.

Déclaration de conflit d'intérêts

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:AMM, EC, AS, ER, and LF are employees of Evidation Health, Inc., developers of the Evidation health and research platform.

Références

Patterns (N Y). 2020 Dec 13;2(1):100188
pubmed: 33506230
N Engl J Med. 2021 Jun 10;384(23):2187-2201
pubmed: 33882225
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
JMIR Res Protoc. 2019 Jan 21;8(1):e10974
pubmed: 30664491

Auteurs

Aziz M Mezlini (AM)

Evidation Health, Inc., 63 Bovet Rd. #146, San Mateo, CA 94402, USA.

Eamon Caddigan (E)

Evidation Health, Inc., 63 Bovet Rd. #146, San Mateo, CA 94402, USA.

Allison Shapiro (A)

Evidation Health, Inc., 63 Bovet Rd. #146, San Mateo, CA 94402, USA.

Ernesto Ramirez (E)

Evidation Health, Inc., 63 Bovet Rd. #146, San Mateo, CA 94402, USA.

Helena M Kondow-McConaghy (HM)

Oak Ridge Institute of Science and Education, 1299 Bethel Valley Rd, Oak Ridge, TN 37830, USA.

Justin Yang (J)

Biomedical Advanced Research and Development Authority, Office of the Assistant Secretary for Preparedness and Response, US Department of Health and Human Services, 200 Independence Ave., Washington, DC 20201, USA.

Kerry DeMarco (K)

Biomedical Advanced Research and Development Authority, Office of the Assistant Secretary for Preparedness and Response, US Department of Health and Human Services, 200 Independence Ave., Washington, DC 20201, USA.

Pejman Naraghi-Arani (P)

Biomedical Advanced Research and Development Authority, Office of the Assistant Secretary for Preparedness and Response, US Department of Health and Human Services, 200 Independence Ave., Washington, DC 20201, USA.

Luca Foschini (L)

Evidation Health, Inc., 63 Bovet Rd. #146, San Mateo, CA 94402, USA.

Classifications MeSH